Latest Regulatory Uncertainty News

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its Phase 1b trial of PYC-003 for Polycystic Kidney Disease, alongside regulatory clearance for an Open-Label Extension allowing continuous dosing up to 24 months.

PEXA contested IPART’s regulatory approach to setting its Initial Asset Base during a public hearing, warning that the proposed valuation could jeopardise its financial sustainability and operational stability.

PYC Therapeutics reports durable retinal gene expression and visual improvements from its PYC-001 candidate in Autosomal Dominant Optic Atrophy, supporting longer dosing intervals and expansion into glaucoma research.

Admiralty Resources has pushed its Mariposa Iron Ore Project into pre-production, completed initial shipments, and raised $7 million in a rights issue, while reporting a $4 million loss for FY25 amid ongoing operational and financial challenges.

Biotron Limited has met the first milestone in its Sedarex acquisition by securing pivotal regulatory feedback from the European Medicines Agency, charting a clearer path for its next-generation anaesthetic SedRx.

Magnum Mining has secured Jack Lifton, a globally recognised rare earth expert, to steer business development as it advances its Piracanjuba North drilling campaign in Brazil.

Hawk Resources has launched an options offer following a $3 million placement, aiming to fund exploration at its scandium and copper projects in Australia and the US.

Xingye Gold has increased its takeover bid for Far East Gold to $0.15 per share, conditional on securing majority ownership by 21 July 2026, and extended the offer period to 29 July. The improved price offers a significant premium amid ongoing project and financial risks at Far East Gold.

Marquee Resources (ASX:MQR) is raising just over $1 million through a non-renounceable rights issue priced at half a cent per share, accompanied by free attaching options. The capital raise aims to support ongoing exploration and the recent acquisition of the Tungsten Mountain Project in Nevada.

Alterity Therapeutics has secured official FDA confirmation that a single pivotal Phase 3 trial, backed by prior Phase 2 data, can support approval of ATH434 for Multiple System Atrophy. Trial initiation remains on track for late 2026.

Enlitic has locked in binding commitments for a conditional A$15 million capital raise alongside a convertible note conversion, setting the stage for a clearer path to cashflow break-even and accelerated rollout of its SaaS platform.

Brazilian Critical Minerals releases a robust Bankable Feasibility Study for its Ema Rare Earth Project, highlighting a US$1.47 billion post-tax NPV and a swift 0.5-year payback period, underpinned by low capital and operating costs.